VELOCITY Failure For Versartis's Lead Drug Sends Shares Into Tailspin
Versartis's long-acting growth hormone product missed Phase III non-inferiority endpoint, wiping more than 83% of the company's value.
You may also be interested in...
Versartis has signed the first licensing deal for its long-acting growth hormone product, tapping Teijin as a commercial partner in Japan.
Shares of Versartis rocketed 33.2% on 6 July after the FDA lifted the partial clinical hold on the firm's investigational new drug application for its long-acting form of recombinant human growth hormone (rhGH) VRS-317, which is being investigated to treat growth hormone deficiency (GHD).
Scrip surveys the Phase III clinical trial readout landscape and picks 10 of the more interesting studies set to report in 2023, with a few added extras. AstraZeneca, Novo Nordisk, Novartis and Roche feature heavily.